Search clinical trials for: BI 891065

Total 1287 results

Boehringer Ingelheim

Completed

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer

Neoplasms

Canada, Netherlands
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

Hepatitis C

Germany
Boehringer Ingelheim

Completed

A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer

Neoplasms

Japan, Taiwan
Boehringer Ingelheim

Completed

BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

Leukemia, Myeloid, Acute

Austria, Germany
Boehringer Ingelheim

Completed

Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

Schizophrenia | Alzheimer Disease

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Obesity | Non-alcoholic Fatty Liver Disease

United States
Boehringer Ingelheim

Completed

This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body

Healthy

Netherlands
Children's Hospital of Philadelphia
Philips Respironics

Completed

Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA

Obstructive Sleep Apnea

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

BI 894999 First in Human Dose Finding Study in Advanced Malignancies

Neoplasms | NUT Carcinoma

United States, Spain, Belgium, Germany, France, Korea, Republic of
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 1015550 Are Taken up in the Body of Healthy Japanese Men

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body

Healthy

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Pancreatic Neoplasms

Austria, Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein

Healthy

Belgium
Boehringer Ingelheim

Completed

Dose Finding Study of BI 836880 in Patients With Solid Tumors

Neoplasms

Germany, France
Boehringer Ingelheim

Completed

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body

Healthy | Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body

Healthy | Chronic Kidney Disease

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Netherlands
Boehringer Ingelheim

Completed

Weekly BI 836880 in Patients With Advanced Solid Tumors

Neoplasms

Spain, France
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

Neoplasms

Hungary
Boehringer Ingelheim

Completed

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse

Leukemia, Myeloid, Acute

United States
Boehringer Ingelheim

Completed

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Wet Macular Degeneration

Austria, Germany, Hungary
Boehringer Ingelheim

Completed

Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

BI 811283 in Various Solid Tumours

Neoplasms

Germany
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Not yet recruiting

A Follow-up Study to Test Long-term Treatment With BI 1015550 in People With Pulmonary Fibrosis Who Took Part in a Previous Study With BI 1015550 (FIBRONEER™-ON)

Idiopathic Pulmonary Fibrosis | Progressive Pulmonary Fibrosis
Boehringer Ingelheim

Active, not recruiting

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Geographic Atrophy

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1595043 is Taken up in the Body When Given With or Without Food

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test How Food Influences the Amount of BI 1323495 in the Blood of Healthy Men

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems

Healthy | Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 690517 in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.

Healthy

United Kingdom
Boehringer Ingelheim

Terminated

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Belgium, Bulgaria, Germany, Greece, Netherlands, Poland, Portugal, Spain
Boehringer Ingelheim

Completed

Phase I Trial of BI 836845 for Various Solid Cancer

Neoplasms

Taiwan
Boehringer Ingelheim

Completed

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

Neoplasms
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee

Osteoarthritis

Germany
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1358894 is Taken up and Handled by the Body

Healthy

Netherlands
Dr Phillip J Buckhurst
BMI Southend Hospital

Completed

Clinical Investigation of the Bi Flex M Multifocal IOL

Cataract
Boehringer Ingelheim

Completed

Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823

Healthy

Germany
Boehringer Ingelheim

Completed

Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic Patients

Healthy | Asthma

United Kingdom

3

Subscribe